These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31685749)

  • 1. (S)-1,2,3,4-Tetrahydroisoquinoline Derivatives Substituted with an Acidic Group at the 6-Position as a Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonist.
    Morishita K; Miike T; Takeda S; Fukui M; Ito Y; Kitao T; Ozawa SI; Hirono S; Shirahase H
    Chem Pharm Bull (Tokyo); 2019; 67(11):1211-1224. PubMed ID: 31685749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Evaluation of a Novel Series of 2,7-Substituted-6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonists.
    Morishita K; Ito Y; Otake K; Takahashi K; Yamamoto M; Kitao T; Ozawa SI; Hirono S; Shirahase H
    Chem Pharm Bull (Tokyo); 2021; 69(4):333-351. PubMed ID: 33790079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 2,7-Substituted (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acids: Peroxisome Proliferator-Activated Receptor γ Partial Agonists with Protein-Tyrosine Phosphatase 1B Inhibition.
    Otake K; Azukizawa S; Takeda S; Fukui M; Kawahara A; Kitao T; Shirahase H
    Chem Pharm Bull (Tokyo); 2015; 63(12):998-1014. PubMed ID: 26633022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Acyl-3-carboxyl-tetrahydroisoquinoline Derivatives: Mixed-Type PTP1B Inhibitors without PPARγ Activation.
    Morishita K; Shoji Y; Fukui M; Ito Y; Kitao T; Ozawa SI; Hirono S; Shirahase H
    Chem Pharm Bull (Tokyo); 2018; 66(12):1131-1152. PubMed ID: 30504630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition.
    Otake K; Azukizawa S; Fukui M; Kunishiro K; Kamemoto H; Kanda M; Miike T; Kasai M; Shirahase H
    Bioorg Med Chem; 2012 Jan; 20(2):1060-75. PubMed ID: 22197396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel series of (S)-2,7-substituted-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor α/γ dual agonists with protein-tyrosine phosphatase 1B inhibitory activity.
    Otake K; Azukizawa S; Fukui M; Shibabayashi M; Kamemoto H; Miike T; Kunishiro K; Kasai M; Shirahase H
    Chem Pharm Bull (Tokyo); 2011; 59(10):1233-42. PubMed ID: 21963632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Acyl-tetrahydroisoquinoline-3-carboxylic acids: lead compounds with triple actions, peroxisome proliferator-activated receptor α/γ agonist and protein-tyrosine phosphatase 1B inhibitory activities.
    Otake K; Azukizawa S; Takahashi K; Fukui M; Shibabayashi M; Kamemoto H; Kasai M; Shirahase H
    Chem Pharm Bull (Tokyo); 2011; 59(7):876-9. PubMed ID: 21720040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
    Henry JR; Li Y; Warshawsky AM; Brozinick JT; Hawkins ED; Misener EA; Briere DA; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Ajamie RT; Wilken B; Devanarayan V
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6293-7. PubMed ID: 17005393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Podophyllotoxin Derivatives as Partial PPARγ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes.
    Zhang X; Liu H; Sun B; Sun Y; Zhong W; Liu Y; Chen S; Ling H; Zhou L; Jing X; Qin Y; Xiao T; Sun T; Zhou H; Yang C
    Sci Rep; 2016 Nov; 6():37323. PubMed ID: 27853282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: a novel series of PPAR gamma agonists.
    Azukizawa S; Kasai M; Takahashi K; Miike T; Kunishiro K; Kanda M; Mukai C; Shirahase H
    Chem Pharm Bull (Tokyo); 2008 Mar; 56(3):335-45. PubMed ID: 18310946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of KY-903, a Novel Tetrazole-Based Peroxisome Proliferator-Activated Receptor γ Modulator, in Male Diabetic Mice and Female Ovariectomized Rats.
    Ito Y; Yamamoto M; Furukawa S; Fukui M; Morishita K; Kitao T; Shirahase H
    Biol Pharm Bull; 2021; 44(5):659-668. PubMed ID: 33952822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin sensitization by a novel partial peroxisome proliferator-activated receptor γ agonist with protein tyrosine phosphatase 1B inhibitory activity in experimental osteoporotic rats.
    Kubo M; Fukui M; Ito Y; Kitao T; Shirahase H; Hinoi E; Yoneda Y
    J Pharmacol Sci; 2014; 124(2):276-85. PubMed ID: 24553405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
    Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
    Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice.
    Huan Y; Pan X; Peng J; Jia C; Sun S; Bai G; Wang X; Zhou T; Li R; Liu S; Li C; Liu Q; Liu Z; Shen Z
    Diabetes Obes Metab; 2019 Nov; 21(11):2553-2563. PubMed ID: 31364797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
    Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
    J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
    Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
    J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.
    Huang F; Zeng Z; Zhang W; Yan Z; Chen J; Yu L; Yang Q; Li Y; Yu H; Chen J; Wu C; Zhang XK; Su Y; Zhou H
    Eur J Med Chem; 2021 Oct; 222():113542. PubMed ID: 34118723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
    Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists.
    Furukawa A; Arita T; Fukuzaki T; Satoh S; Mori M; Honda T; Matsui Y; Wakabayashi K; Hayashi S; Araki K; Ohsumi J
    Bioorg Med Chem Lett; 2012 Feb; 22(3):1348-51. PubMed ID: 22225641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.